Okla. Admin. Code § 475:30-1-4 - Manner of issuance of prescriptions
(a) The practitioner
shall sign a prescription in the same manner he/she would sign a check or legal
document and shall also type, stamp, or print the practitioner's name on the
face of each prescription. Where an oral order is not permitted or an
electronic prescription is not utilized, prescriptions shall be written with
ink. All written prescriptions shall be manually signed by the practitioner.
The prescriptions may be prepared by an agent for the signature of a
practitioner, but the prescribing practitioner is responsible in the event the
prescription does not conform in all essential respects to the Uniform
Controlled Dangerous Substances Act and this Chapter.
(b) A resident or staff practitioner, an
intern of a teaching hospital, or a limited institutional practitioner of a
federal, state, or local government hospital or institution, exempted from
registration or registered in fee-exempt status with the Oklahoma State Bureau
of Narcotics and Dangerous Drugs Control (OBN), shall include on all
prescriptions issued by him/her the hospital or institutional Federal Drug
Enforcement Administration (DEA) registration number with the special internal
code number assigned by the hospital or other institution; or include on all
prescriptions he/she issues his/her personal DEA registration number. Such
prescriptions issued by interns of a teaching hospital, if for outpatients,
must be countersigned by a practitioner licensed by the practitioner's
appropriate State of Oklahoma licensing board.
(c) A practitioner must state on a
prescription for any controlled dangerous substance the name, address, and DEA
registration number of the practitioner; the date of delivery of the
prescription; the name, dosage, and strength per dosage unit of the controlled
dangerous substance; the name and address of the patient, or if it is a
veterinary prescription, the species of the animal and the name and address of
the owner; the directions for use and any cautionary statements required; and
if allowable, the number of times to be refilled.
(1) The face of a prescription must not be
materially altered; if an error is made in filling out the prescription, a new
prescription must be issued by the prescribing practitioner.
(A) A pharmacist may add to the prescription
the patient's address or age, the prescribing practitioner's DEA registration
number, or the generic drug name if used.
(B) After confirming with the prescribing
practitioner, the pharmacist may add information indicating the strength,
whether tablet or capsule form, and whether it is compounded if such additions
would not materially alter the prescription.
(C) If omitted, the directions (Sig) or the
quantity, may be added by the pharmacist after confirming with the prescribing
practitioner.
(D) Documentation of
contacting the prescribing practitioner will be noted on the back of the
prescription regarding (B) and (C) above.
(2) A prescription for a controlled dangerous
substance in Schedule II becomes invalid thirty (30) days after the earliest
date on which a pharmacy may fill the prescription, with day one (1) of the
thirty (30) day period being the first day after the earliest date on which a
pharmacy may fill the prescription. After issuing an initial prescription
pursuant to Section
2-309I of Title 63, an individual
practitioner may issue one (1) subsequent prescription for an immediate-release
opioid drug in Schedule II in a quantity not to exceed seven (7) days if:
(A) The subsequent prescription is due to a
major surgical procedure and/or "confined to home" status as defined in
42 U.S.C.
1395n(a);
(B) The practitioner provides the subsequent
prescription on the same day as the initial prescription;
(C) The practitioner provides written
instruction on the subsequent prescription indicating the earliest date on
which the prescription may be filled (i.e. "do not fill until" date);
and,
(D) The subsequent
prescription is dispensed no more than five (5) days after the "do not fill
until" date indicated on the prescription.
(3) Each scheduled drug shall be written on a
single prescription form, and no other prescriptions (controlled or
non-controlled) shall be written on the same prescription form.
(d) Upon receiving an oral
prescription, the pharmacist must reduce the oral prescription to the form
specified in (c) of this Section, including the typewritten name of the
prescribing practitioner. The pharmacist filling any prescription for any
controlled dangerous substance must enter the date of filling and handwrite the
initials of the pharmacist on the prescription. If the practitioner is not
known to the pharmacist, he/she must make a reasonable effort to determine that
the oral authorization came from a registered practitioner.
(e) Upon receiving an oral prescription, the
pharmacist may use a computer printout label if the label meets all
requirements for a prescription as set out by the Uniform Controlled Dangerous
Substances Act and this Chapter. On computer labeling for oral prescriptions,
it is not necessary that the DEA registration number be on the label used as an
oral prescription, but it must be recorded on the document prepared by the
pharmacist.
(f) Written
prescriptions may be transmitted by a practitioner to a dispensing pharmacy by
facsimile. In such cases, the prescribing practitioner shall print "FAXED" on
the face of the prescription, and the facsimile received must be on non-fading
standard paper. Thermographic paper is not acceptable for any prescriptions for
drugs in any Schedule.
(1) For drugs in
Schedules III, IV, and V, a facsimile of a written, signed prescription
transmitted directly by the prescribing practitioner to the pharmacy can serve
as an original prescription.
(2)
For drugs in Schedule II, the original written prescription must still be
presented and verified against the facsimile at the time the substance is
actually dispensed and the original document must be properly annotated and
retained for filing subject to the exceptions listed in (3) below.
(3) Exception to (2): A facsimile copy of a
prescription for a Schedule II drug when sent by facsimile by the prescribing
practitioner:
(A) To a Home Infusion
Pharmacy.
(B) When the prescription
is for a patient in a Long Term Care Facility (LTCF).
(C) When the prescription is for a patient in
a Hospice program certified by Medicare under Title XVIII or licensed by the
state.
(D) If the facsimile is sent
from a LTCF or hospice instead of the prescribing practitioner's office, the
original must be presented at the time any controlled dangerous substance is
dispensed.
(g)
The pharmacist still bears the responsibility for ensuring that prescriptions
for controlled dangerous substances have been issued for a legitimate medical
purpose by an individual practitioner acting in the usual course of his/her
professional practice. This responsibility applies equally to an order
transmitted by facsimile. Measures to be considered in authenticating
prescriptions sent by facsimile equipment would include maintenance of a
practitioner's facsimile number reference file, verification of the telephone
number of the originating facsimile equipment, and/or telephone verification
with the practitioner's office that the prescription was both written by the
practitioner and transmitted by the practitioner or the practitioner's
agent.
(h) Electronic prescriptions
are permitted as provided by 21 CFR §§ 1311 et. seq.
Notes
Amended at 12 Ok Reg 2847, eff 7-15-95 ; Amended at 22 Ok Reg 2683, eff 7-25-05 ; Amended at 24 Ok Reg 2741, eff 8-11-07 ; Amended at 29 Ok Reg 1320, eff 6-25-12 ; Amended at 30 Ok Reg 546, eff 5-13-13
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.